2024-11-07 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. 

The cumulative return for JNJ is **31.61%**, while the S&P 500 (VOO) has a cumulative return of **139.88%**. This puts JNJ significantly behind the market benchmark. The relative divergence currently stands at **-108.27**, indicating that JNJ has significantly underperformed the market over the analyzed period.

The alpha and beta analysis shows mixed performance:

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|-------|
| 2015-2017 | 33.7% | 10.1% | 3.5% | 0.7 |
| 2016-2018 | 28.4% | 17.5% | 3.8% | 0.7 |
| 2017-2019 | 25.9% | 17.5% | -17.1% | 0.7 |
| 2018-2020 | 13.0% | 27.5% | -26.1% | 0.7 |
| 2019-2021 | 33.9% | 27.5% | -55.9% | 0.6 |
| 2020-2022 | 21.0% | 27.5% | 3.3% | 0.5 |
| 2021-2023 | 0.1% | 16.6% | -28.7% | 0.3 |
| 2022-2024 | -8.0% | 16.6% | -31.6% | 0.2 |

While JNJ has generally outperformed the market in terms of CAGR, its alpha has been volatile and generally negative, suggesting that it hasn't generated significant returns beyond what would be expected based on market risk. 

**2. Recent Price Movement**

* **Closing Price:** $157.88
* **5-day Moving Average:** $158.89
* **20-day Moving Average:** $161.75
* **60-day Moving Average:** $162.64

The current price is below all three moving averages, indicating a potential downtrend. 

**3. Technical Indicators**

* **RSI:** 30.83 (Below 30, indicating oversold conditions)
* **PPO:** -0.33 (Negative value, indicating potential bearish momentum)
* **Delta_Previous_Relative_Divergence:** -4.19 (Negative value, indicating a recent short-term downward trend)
* **Expected Return:** 0.0% (The expected long-term (2 years+) return relative to the S&P 500 is currently estimated to be neutral, meaning there is no significant expected outperformance compared to the benchmark)

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

JNJ has been experiencing some volatility in its earnings performance, but it has generally been consistent in exceeding revenue expectations. The most recent earnings release (2024-10-23) is not yet reflected in the above table and needs further analysis compared to analysts' expectations to properly evaluate the performance. 

**5. Financial Information**

1) **Revenue and Profitability**

| Quarter  | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

JNJ has consistently maintained a strong profit margin, indicating robust revenue growth and efficient cost management. 

2) **Capital and Profitability**

| Quarter  | Equity    | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

JNJ demonstrates strong financial health with high equity levels and a consistently high ROE. 

**6. News and Recent Issues**

* **Recent Earnings Releases:** Analyze the most recent earnings report released on 2024-10-23 (shacknews, etc.) and compare it to analysts' expectations. This includes analyzing the company's guidance for future earnings and revenue growth.
* **Recent Market Outlook:** Analyze recent news and articles about JNJ from reliable sources (Finbold, etc.) This includes examining any new developments, partnerships, or regulatory approvals that could affect the stock's performance.
* **Analyst Opinions:** Research the opinions of analysts covering JNJ. Identify the key factors they consider and their outlook on the stock's performance.

**7. Overall Analysis**

Johnson & Johnson is a strong company with a long history of consistent performance and strong financial health. However, its recent underperformance compared to the market and the negative alpha raises concerns about its future prospects. The current oversold conditions indicated by the RSI might offer a potential buying opportunity, especially for long-term investors. However, it is crucial to carefully analyze the recent earnings report and assess the impact of any relevant news and analyst opinions.

**Disclaimer:** This is an informational report and should not be considered investment advice. Please consult with a financial professional for personalized investment guidance.